Dr. Scagliotti on the Phase III ASCEND-5 Study in ALK+ NSCLC

Giorgio Scagliotti, MD, PhD
Published: Tuesday, Oct 11, 2016



Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

The study compared the efficacy and safety of ceritinib (Zykadia) to standard second-line chemotherapy (pemetrexed or docetaxel) in patients with advanced ALK+ non-small cell lung cancer (NSCLC) who progressed on prior crizotinib (Xalkori) and 1 or 2 prior regimens of chemotherapy.

According to Scagliotti, the results of the study were both clinically and statistically meaningful. Median progression-free survival was significantly improved with ceritinib compared to chemotherapy (5.4 vs 1.6 months).


Giorgio Scagliotti, MD, PhD, professor of Medical Oncology, University of Torino, discusses the design and the results of the phase III ASCEND-5 study during an interview at the 2016 ESMO Congress.

The study compared the efficacy and safety of ceritinib (Zykadia) to standard second-line chemotherapy (pemetrexed or docetaxel) in patients with advanced ALK+ non-small cell lung cancer (NSCLC) who progressed on prior crizotinib (Xalkori) and 1 or 2 prior regimens of chemotherapy.

According to Scagliotti, the results of the study were both clinically and statistically meaningful. Median progression-free survival was significantly improved with ceritinib compared to chemotherapy (5.4 vs 1.6 months).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x